Clinical Success Articles & Analysis
30 articles found
By providing a platform that accurately reflects human biology, organ-on-a-chip systems allow for the identification of adverse drug reactions early in the discovery process, thereby increasing the likelihood of success in clinical trials. Furthermore, advancements in genomics and proteomics have paved the way for the creation of more refined disease models. ...
Medical advancement relies on clinical trials, which are essential for the development of safe and effective innovative treatments. However, the success and general applicability of these treatments heavily depend on the diversity of the participants ...
This strategy had its earliest clinical success with Mylotarg and was later used in Besponsa. However, the stability of the acid-cleavable linker severely limits its application in ADCs. ...
This strategy achieved the earliest clinical success with Pfizer's Mylotarg® (AcBut Linker). Although reducible disulfides are also employed, linker contains an acid-sensitive N-acylhydrazone linkage. ...
Before a new drug candidate can progress to clinical trials and ultimately reach the market, it needs to undergo rigorous testing in various model systems to assess its efficacy and safety. ...
Through its bioactive peptide finder, Magnifier NπΦ, the company can boast a clinical trial success rate of 80%. Development of an ingredient goes through three phases, from discovery to preclinical biology testing and clinical trials. ...
As part of our quick fire questions series – or QFQs – we spoke to Dr. Andy Franklyn-Miller, Chief Medical and Innovation Officer at Nuritas about intelligent ingredients, explaining peptides and proving an AI model in life science. There is a lack of innovation within ingredients in food, many have been discovered decades ago, mostly with cost, taste and texture in mind. However as ...
Drugs such as the anti PD-1 antibody bind immune checkpoint molecules on T cells, so that cancer cells cannot bind them to inhibit T cell function. These drugs have shown some success; the caveat is that while immune cell function is no longer hampered with regards to cancer cells, it is not targeted to tumor-specific T cells. ...
The ability to fabricate complex 3D structures containing live cells for drug discovery and tissue engineering has huge potential. To realise successful clinical translation, biologistics need to be considered. Refinements in the storage and transportation process from sites of manufacture to the clinic will enhance the success ...
Accuracy in medical coding is a vital aspect in aiding clinical trial operation success. It has presented an excellent opportunity for medical coders, working hand-in-hand with AI-enhanced computer-assisted coding systems, to quickly identify and validate the correct codes. ...
ByClinion
For example, the drug developer has initiated four new clinical trials in 2022 alone. It's also a promising sign of strength for investors, although long-term performance will be driven by execution and clinical trial data. ...
The Clinical CRISPR Successes Are Stacking Up. But Where’s the Emphasis on Quality Control? ...
The Holiday season often brings mixed feelings for many. While it can be a time of relaxation with friends and family for some, for others, preparing for this time means ensuring business continuity despite a typical slow down. This can be a source of undue stress if it is not suitably planned for. ...
By applying a proprietary operating system to drug discovery, the Utah clinical-stage biotechnology company expects to turn drug discovery from sequential testing into a search problem. Unmet clinical needs often serve as the fundamental driving force behind drug discovery programs. During lead discovery, an intensive search ensues to find a drug-like small ...
SmartTab is pioneering a wireless remote controlled drug delivery system, has completed pre-clinical animal studies and is preparing for human clinical trials for its core technology TargetTab™. ...
BySmartTab
Investigational bioengineered human acellular vessels (HAVs) have shown clinical success and may confer lower susceptibility to infection. Here we directly compared the susceptibility of ePTFE grafts and HAV to bacterial contamination in a preclinical model of infection Materials and methods: Sections (1 cm2 ) of ePTFE (n ¼ 42) or HAV (n ¼ 42) were ...
DR Systems. Inc.. is a leading provider of integrated medical image management systems for hospitals and imaging centers. Co-founded in 1992 by practicing radiologist Murray Reicher, M.D.. the company has become one of the preeminent vendors in the PACS industry and serves facilities of all sizes, ranging from one of the smallest hospitals in the United States to large academic medical centers ...
I’m always researching ways we can improve our production and testing methods to ensure our Phase 2 Progenza™ product is successful. Q. What is your focus for the next 12 months? A. The main areas I will be focusing over the next 12 months are technical management and guidance for our Phase 2 trial and further development towards commercialisation. ...
Brian Firth, another of Marv's former colleagues from J&J, joined us as our Chief Scientific Officer and has been a major contributor to our success while leading our R&D, Clinical and Regulatory programs. ...
An unmet need for disease-modifying therapy persists for patients with Systemic Sclerosis SSc is an autoimmune disease characterised by widespread vascular injury, progressive fibrosis of the skin and internal organs, and a specific pattern of autoantibodies. The clinical manifestations of SSc are highly heterogenous with significant internal organ manifestations causing a ...